Alexandre Zerbib

Launch Lead Transplant in pharma industry #Hematology #GVHD #Myeloma #MissingType #Surgery #Marketing #Astronomy Tweets are my own

[Talha Badar @TalhaBadarMD]

#Weekend_review #menin_inhibitor #leusm 🧵 Menin inhibitors in AML: biology → approvals → combinations → resistance

1/9
Menin inhibition has rapidly moved from a biological concept to an established therapeutic strategy in AML.

Why does it work?

KMT2A-r and NPM1-mut AML are genetically distinct—but both converge on the HOXA/MEIS1 transcriptional program, which maintains leukemic stemness and blocks differentiation.

Menin helps sustain this program.

Menin interacts with KMT2A and helps maintain transcription of genes including HOXA9 and MEIS1.

Blocking the menin–KMT2A interaction suppresses this leukemic program and promotes myeloid differentiation.

Importantly, mutant NPM1 also creates a transcriptional state dependent on this axis:

KMT2A-r → MENIN/HOX-MEIS ← NPM1-mut

Think of menin inhibition fundamentally as a differentiation strategy, not simply cytotoxic therapy.

[Alexandre Zerbib @AlexandreZerbib]

May the 4th be with you #transplant and #myeloma community !!!

[Benlazar S M A @smbenlazar]

Hypomethylating Agents and Venetoclax Based Triplets Targeting FLT3, IDH and KMT2A in Acute Myeloid Leukemia: Current Studies and Challenges of a Tailored Approach https://t.co/cHZK5FxUmh #mdpicancers via @Cancers_MDPI #leusm

[Benlazar S M A @smbenlazar]

Management of Acute Myeloid Leukemia: A Review https://t.co/D6oZNHErUv #mdpicancers via @Cancers_MDPI #leusm

[Raul Cordoba, MD, PhD @DrRaulCordoba]

#Hematology The treatment of marginal zone #lymphoma #MZL #lymsm https://t.co/mBrfx0HB9x

[Dr Rudra Narayan Swain M.D , D.M @rudra09s025]

Excellent chapter in the #ASH25_Education_book and lecture on
🧬 Post-alloHCT maintenance in AML @Mark_J_levis from @HopkinsMedicine

🔹 Strongest evidence in FLT3-ITD AML
🔹 Benefit driven by MRD status + immune synergy (IL-15, GvL)
🔹 Not all targets are equal: FLT3 > Menin (emerging) > IDH (selective)
🔹 Parenteral AZA → negative randomizsed data
🔹 Oral AZA (CC-486) → no proven OS/RFS benefit post-HCT
Take-home:
👉 MRD-guided, biology-directed maintenance should be the goal.
📚 Key trials & data
• SORMAIN – JCO 2020
• Xuan et al. – JCO 2021
• MORPHO – Blood 2023
• FLT3–IL-15 immune synergy – Nat Med 2018
• Menin inhibitors in KMT2A AML – NEJM 2023
Oran et al. Blood 2020
• AMADEUS trial – CC-486 post-HCT (results awaited / no signal yet)
• VIAL-T – AZA/VEN post-HCT (terminated)

#AML #AlloHCT #ASH25 @ASH_hematology @BloodPortfolio @ASHEducationbook @OncoAlert @AML_Hub @ASTCT

[Alexandre Zerbib @AlexandreZerbib]

Day 1 at #ASH25.
Ready to start 5 days of an intensive and wonderful congress.
#transplant #cgvhd #myeloma #ITP and so many others topics.

[Raul Cordoba, MD, PhD @DrRaulCordoba]

“The calm before the storm” #ASH25 #hematology

[Alexandre Zerbib @AlexandreZerbib]

Supporting #breastcancer research with #runrose Meudon 🏃🏃🏃‍♀️🏃‍♂️

[Alexandre Zerbib @AlexandreZerbib]

Donor choice by ⁦@Mohty_EBMT⁩ at #IACH 2025

[Alexandre Zerbib @AlexandreZerbib]

⁦@A_Bobin_⁩ presenting during #IACH 2025 in Paris on new mode of drug delivery

[Alexandre Zerbib @AlexandreZerbib]

May the 4th be with you
#StarWars

[Douaa Dhahri @DouaaDhahri]

What a great way to wrap up the congress of the French Society of Hematology #SFH2025! Gaining insights from Michel Sadelain on the past and future advancements of CAR-T cells.

[Sanofi @sanofi]

Graft-versus-host disease can occur post stem cell transplant, affecting quality of life. Low awareness of the diverse #GVHD symptoms may potentially impact diagnosis and outcomes.

On this #GVHDDay, we recognize the importance of raising awareness to prompt patients to seek help

[Sanofi @sanofi]

#GVHDDay makes this the ideal time to learn the ABCs of Graft-Versus-Host-Disease.

Sometimes severe, this complication is experienced by about half those transplanted with donor cells.

Visit to find out more and show your support. ⤵️

#GVHDAlliance #GVHDConnectForHope

[Julien FEBREAU @Julien_FEBREAU]

#RDVau1erVirage2025 #LewisHamilton #Legend #LHistoireContinue #BandeAnnonce #CanalPlus

[Alexandre Zerbib @AlexandreZerbib]

Last Day at #ASH2024. After an incredible week back to home. Plane ready to go…Bye bye San Diego!

[Alexandre Zerbib @AlexandreZerbib]

Last Day at #ASH2024 … people are leaving San Diego… Hopefully Presidential Symposium still crowded!

[Alexandre Zerbib @AlexandreZerbib]

Day 3 at #ASH2024
What a great French team present in San Diego for learning from experts on #cGVHD management
Darko Kiprijanovski @frieastrid

[Alexandre Zerbib @AlexandreZerbib]

For beginning the Day2 at #ASH2024